Viridian Therapeutics Stock Forecast

Buy or Hold candidate since Jun 22, 2026 Loss -1.76%

The Viridian Therapeutics, Inc. stock price gained 0.231% on the last trading day (Wednesday, 24th Jun 2026), rising from $17.28 to $17.32. During the last trading day the stock fluctuated 3.43% from a day low at $17.19 to a day high of $17.78. The price has been going up and down for this period, and there has been a 6.19% gain for the last 2 weeks. Volume fell on the last day by -440 thousand shares and in total, 1 million shares were bought and sold for approximately $21.21 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $17.73 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall -9.48% during the next 3 months and, with a 90% probability hold a price between $11.01 and $16.05 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

VRDN Signals & Forecast

The Viridian Therapeutics, Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $16.84 and $16.82. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Tuesday, May 05, 2026, and so far it has fallen -7.63%. Further fall is indicated until a new bottom pivot has been found.

Support, Risk & Stop-loss for Viridian Therapeutics, Inc. stock

Viridian Therapeutics, Inc. finds support from accumulated volume at $16.97 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.590 between high and low, or 3.43%. For the last week, the stock has had daily average volatility of 4.86%.

Our recommended stop-loss: $16.40 (-5.32%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 34 days ago.)

Trading Expectations (VRDN) For The Upcoming Trading Day Of Thursday 25th

For the upcoming trading day on Thursday, 25th we expect Viridian Therapeutics, Inc. to open at $17.43, and during the day (based on 14 day Average True Range), to move between $16.89 and $17.75, which gives a possible trading interval of +/-$0.86 (+/-5.10%) up or down from last closing price. If Viridian Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 5.10% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $17.53 (1.21%) than the support at $16.97 (2.02%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Viridian Therapeutics, Inc. stock A Buy?

Viridian Therapeutics, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

Current score: -0.668 Hold/Accumulate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on June 25, 2026 - $17.43 ( 0.616%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk